Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Top Page
Aprea Therapeutics
(NASDAQ:APRE)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.69
▲(2.99% Upside)
Action:ReiteratedDate:03/17/26
The score is held down primarily by weak fundamentals—ongoing losses, cash burn, and inconsistent/limited revenue—alongside a technically weak price trend below key moving averages. Offsetting factors include low leverage and positive corporate updates (early clinical activity for APR-1051 and extended cash runway via financing), but these are not yet sufficient to outweigh the current financial and trend risks.
Positive Factors
Early clinical proof‑of‑concept (APR‑1051)
Emerging unconfirmed responses and multiple stable disease cases in genomically defined patients provide durable evidence APR-1051 can hit its intended target population. Such early PoC supports focused development, de-risks strategy, and justifies cohort expansion and partner interest over the next 2–6 months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicates the company must rely on external financing to sustain operations. Ongoing burn erodes cash reserves and forces periodic capital raises, a structural vulnerability for a clinical-stage biotech without product revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Early clinical proof‑of‑concept (APR‑1051)
Emerging unconfirmed responses and multiple stable disease cases in genomically defined patients provide durable evidence APR-1051 can hit its intended target population. Such early PoC supports focused development, de-risks strategy, and justifies cohort expansion and partner interest over the next 2–6 months.
Read all positive factors
Aprea Therapeutics (APRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.02M
Dividend YieldN/A
Average Volume (3M)55.77K
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue Growth-62.75%
EPS Growth23.87%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding11,452,452
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)19.52
P/FCF Ratio-0.43
Enterprise Value/Market Cap-1.25
Enterprise Value/Revenue-35.18
Enterprise Value/Gross Profit-38.07
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$5.33Price Target Upside695.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$150.00K
Aprea Therapeutics Business Overview & Revenue Model
Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that ...
How the Company Makes Money
null...
Aprea Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 285.76K | 1.50M | 583.23K | 0.00 | 0.00 |
| Gross Profit | 264.04K | -7.86M | 576.18K | -16.40M | -271.68K |
| EBITDA | -13.23M | -14.30M | -14.28M | -37.37M | -36.86M |
| Net Income | -12.60M | -12.96M | -14.29M | -112.66M | -36.54M |
Balance Sheet | |||||
| Total Assets | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Cash, Cash Equivalents and Short-Term Investments | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K |
| Total Liabilities | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Stockholders Equity | 12.44M | 19.31M | 18.26M | 25.64M | 49.51M |
Cash Flow | |||||
| Free Cash Flow | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Operating Cash Flow | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Investing Cash Flow | 0.00 | -15.48K | -93.09K | 0.00 | 0.00 |
| Financing Cash Flow | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
Aprea Therapeutics Technical Analysis
Negative
0.67
Price Trends
0.77
Negative
0.92
Negative
1.27
Negative
Market Momentum
-0.03
Positive
42.38
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Negative. The current price of 0.67 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.77, and below the 200-day MA of 1.27, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.38 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APRE.
Aprea Therapeutics Risk Analysis
Aprea Therapeutics disclosed 80 risk factors in its most recent earnings report. Aprea Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aprea Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $20.58M | -0.94 | -74.15% | ― | 6.29% | 7.42% | |
47 Neutral | $8.02M | -0.67 | -87.05% | ― | -62.75% | 23.87% | |
47 Neutral | $11.33M | ― | -334.42% | ― | ― | -228.89% | |
45 Neutral | $14.48M | -0.53 | -189.72% | ― | ― | 70.57% | |
44 Neutral | $6.16M | -0.34 | -253.43% | ― | ― | 94.52% |
* Healthcare Sector Average
APRE
Aprea Therapeutics
0.70
-1.50
-68.18%
ERNA
Eterna Therapeutics
0.21
-3.18
-93.86%
QNRX
Quoin Pharmaceuticals
7.57
-2.41
-24.12%
NCNA
Nucana
1.48
-212.52
-99.31%
VYNE
VYNE Therapeutics
0.62
-1.16
-65.34%
INAB
IN8bio
1.47
-4.77
-76.45%
Aprea Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Aprea Highlights Early APR-1051 Data and Financial Update
Positive
Mar 16, 2026
On March 16, 2026, Aprea reported fourth-quarter and full-year 2025 results and highlighted early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial, where two PPP2R1A-mutated endometrial cancer patients achieve...
Business Operations and Strategy
Aprea Highlights Encouraging Phase 1 Data for APR-1051
Positive
Feb 18, 2026
On February 18, 2026, Aprea Therapeutics reported additional preliminary data from its ongoing first-in-human Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in advanced solid tumors, highlighted by a second unconfirmed partial response in a ...
Business Operations and StrategyPrivate Placements and Financing
Aprea Therapeutics Announces Financing and Early Trial Response
Positive
Jan 29, 2026
On January 28, 2026, Aprea Therapeutics entered into a securities purchase agreement with new and existing healthcare-focused institutional investors and company insiders for a $5.6 million private placement of 6,288,857 shares of common stock (or...
Business Operations and StrategyProduct-Related Announcements
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
Positive
Jan 9, 2026
On January 9, 2026, Aprea Therapeutics updated its corporate presentation, outlining a development roadmap through 2026 that highlights multiple DDR-focused drug candidates and clinical milestones in early-stage oncology trials. The company detail...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.